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Abstract. Isoniazid is one of anti-tuberculosis agent which can cause hepatotoxicity. However, not all of the TB patients 
and health providers can recognize early symptoms of antituberculosis-induced hepatotoxicity. Thus, the Therapeutic 
Drug Monitoring needs to be performed to monitor the hepatotoxicity symptoms. The aim of this study is to establish the 
validity of the Isoniazid assay method using High-Performance Liquid Chromatography from human plasma. We 
recruited 6 healthy subjects for this validation study. The validation was performed using Shimadzu HPLC system with a 
model AT LC20 LC 10AT pump, detector SPD 20A and LC solution software. We used C18 column shim- pack VP-
ODS (250 mm x 4.6 mm, id 5μm) as well as other tools such as centrifuges, vortex, appliance glass (Pyrex IWAKI) and 
other supporting tools. Chemicals and solvents was used from Merck Germany. Isoniazid standard compounds were 
obtained from SIGMA. Our study has been approved by National Ethics Committee of Health Research. Our study shows 
that the method applied in HPLC has the good linearity (r = 0.998) with coefficient of variance (CV) of system 
appropriateness test is 0.61% and the equation of linearity was y=8756.87x+27724.82. The value of Limit of Detection 
(LoD) and Limit of Quantification (LOQ) were 1.517μg/ml and 4.597 μg/ml, respectively. The precision on the 
concentration of 0,5; 5.0; 15.0 ug/ml are 5.24%, 0.79%, 2.83%, respectively for intraday precision and 4.86%; 2.18%; 
2.01%, respectively for interday precision. The recoveries on the particular concentrations are 100.79%; 108.91%; 
92.19%, respectively for intraday recovery and 101.73%; 99.63%; 82.75%, respectively for interday recovery. This 
validation method is a good alternative for the application of TDM in monitoring the treatment of TB patients’ clinical 
practice 
 




Currently, Indonesia is in the 5th rank of the highest tuberculosis prevalence over the world [1]. Since 1995, 
WHO introduced the Directly Observed Treatment Shortcourse (DOTS) program, and this program has been proven 
as effective in controlling the tuberculosis disease. The mortality rate decrease about 45% and the tuberculosis 
prevalence decrease about 42%. However, the incidence of tuberculosis is still high [1,2]. 
Anti-tuberculosis agents which used in the treatment of tuberculosis are isoniazide, rifampicin, ethambutol and 
pyrazinamide. One of the most popular side effect due to the use of the medications are hepatotoxicity [3,4]. 
Isoniazid is the most possible drug caused hepatotoxicity due to its toxic metabolite [5]. 
The incidence of hepatotoxicity due to the use of antituberculosis was 20% [6]. Due to the long duration of 
treatment of tuberculosis, we need to do the monitoring of hepatotoxicity symptomps and provide the appropriate 
treatment [7]. One of the method to do the monitoring is Therapeutic Drug Monitoring (TDM) which is one part of 
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the pharmaceutival care services [8]. TDM may help the physician to understand about the complexity treatment of 
tuberculosis and also help the physician to decide about the dose or treatment recommended after having the results 
of TDM [9]. 
Isoniazid or Isonicotinic acid Hidrazide (INH) is a white or colorless crystals or white crystalline powder and 
odorless. It is slowly affected by air and light and is easily soluble in water, slightly soluble in ethanol, sparingly 
soluble in chloroform and in ether. INH is well absorbed in the gastrointestinal after oral administration and is 
distributed throughout the body. Its peak concentration in serum is depend on the dose administered. The peak 
serum levels achieved within 1-3 hours after oral administration and the effective concentration was found 24 hours 
after the drug is swallowed. The average half-life in fast acetylators reaches nearly 80 minutes, while the value of 
hours is typical for slow acetylator [10]. 
This study objective is to to establish the validity of the Isoniazid assay method using High-Performance Liquid 





We recruited 6 healthy subjects as volunteer of blood plasma sample. The blood was taken 2 hour after the 
antituberculosis agents were taken by the patients. We gave the informed consent to the subject and asked them to 
signature the informed consent form as the agreement for participation in this study. Our study has been approved by 
the National Ethic Committee of Health Research. 
 
Reference Compound and Reagents 
Chemicals and solvents used from Merck Germany, among others: methanol pro analysis (pa) (3906609839), 
Diethyl ether pa, Trichlor solution of acetic acid (TCA) 10% pa (3639707643), pa Acetonitrile (1632730213) and 
aquabidest. The isoniazid as standard compounds was obtained from SIGMA. 
 
Chromatographic Conditions 
This study used a Shimadzu HPLC system with a model of AT LC20 LC 10AT pump, detector SPD 20A and LC 
solution software. The column used was a C18 column shim- pack VP-ODS (250 mm x 4.6 mm, id 5μm). Mobile 
phase consisted of Aquabidest : Acetonitrile (97:3)% with flow rate 1 mL/ minute, UV detection at a wavelength of 
262 nm, retention time 15 minute and inject volume 20 μL. 
 
Preparation of plasma standards and samples 
The standard samples were prepared from 450 μl of plasma, then added by 50 μl validation solution to make 
5.00; 50.00 and 150.00 μg/mL. The solution concentrations for linearity were 0.5; 1.00; 3.00; 5.00 and 15.00 μg/mL. 
The solution concentrations for accuracy, intraday and interday recision were 0.5; 5.0; 15.00 μg/mL. 
The 1000 mL of 10% TCA was added onto each the concentration solutions then follow these procedures such 
as; 20 seconds of vortex for with a maximum speed and 10 minutes of centrifuged at a speed of 13000 rpm, 
temperature of 4°C. The supernatant was poured into the tube and added by 3 mL of ether. The extraction was 
performed using these procedures; 20 seconds of vortex and 10 minutes of centrifuged at 4000 rpm. Finally, the 20 
mL water phase was injected into the HPLC [11,12]. 
 
Validation Method 
The validation method of INH using HPLC was modified from the previous studies [11,12]. We used HPLC due 
to this instrument has high selectivity and sensitivity and it also can perform the analysis with small cancentration of 
sample using UV adsorben detector [13]. 
 
System Suitability 
The system suitability was examined from the one point of 20 μL solution from standard curve which was 
injected into HPLC. We replicated this method for six times. From the chromathoghraph we defined the coefficient 
of variance (CV) of retention time and wide of area ratio [14,15]. 
 
Linearity 
The equation of linier regression: y = bx+a described the association between INH concentration and area wide 
ratio of chromatoghraph or the high of chromatoghraph peak. The calibration curve was used to defined the sample 
concentration. [14,15]. 
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LoD and LoQ 
The value of LoD and LoQ were defined from the equation and standar of deviation (SD). LoD was defines as 
signal and noise ratio (S/N) with the 3:1 comparation. The LoQ was defined using 10:1 comparation of S/N. [14,15] 
 
Accuracy 
The recovery describes the value of accuracy. The Area Under the Curve (AUC) of isoniazid was processed by 
linear regression equation to get the actual levels. The value of recovery can be seen from the average % of recovery 
or actual levels divided theoretical level and multiplied by 100%. The value of good recovery was 80-120%. [14,15] 
 
Intra-day and Inter-day precision 
Intra-day precision values can be seen from the % of coefisien of variance (CV) of each replication. The method 




The results of this study are listed in Table 1. The suitability system shows the CV TR and CV peak area are 
0,26% and 0,61% respectively. The equation for regression linier of 0.5; 1; 3; 5; 10; dan 15 μg/mL concentration is 
y = 8756.873x + 27724.816, with r = 0,998. The regression linier can be seen in Graph 1. The LoD and LoQ met the 
criteria of FDA and ICH [14,15] which are 1.571 μg/mL and 4.597 μg/mL, respectively. 
 




















FIGURE 1. Linearity of INH concentration and AUC 
 
 
Table 2 shows the results of accuray and precision. The accuracy of of this method are shown by % recovery of 
intraday and interday sampel for 0.5; 5.0; and 15.0 μg/mL concentration, which are 100.79%, 108.91%, and 
92.19%, respectively and 101.73%, 99.63%, and 82.75% , respectively. The intraday precision is defined as CV  
(%) from the concentration of 0.5; 5.0 and 15.0 μg/mL are 5.24%, 0.79% and 2. 83%, respectively. Furthermore, 
Parameter Required Criteria* Results 
System suitability CV ≤ 2% CV TR = 0,26% 
CV peak area = 0,61% 
inearity  r ≥ 0,99 r = 0,998  
y = 8756.873x + 27724.816 
LOD S/N ≈ 3:1 1,517 μg/mL 
LOQ S/N ≈ 10:1 4,597 μg/mL 
CV = coefisien of variance; TR = Retention Time; r = Coefficient of correlation; LOD = Limit of Detection; LOQ 
=Limit of Quantification. *Adopted from [14]; [15] 
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the interday precision on those particular concentration are 4.86%, 2.18%, and 2. 01% respectively. 
 
 
TABLE 2. Results of precision and accuracy 
Concentration Mean ± SD Precision Accuracy Required criteria  (μg/mL) (μg/mL) (CV %) (R %)   
 
     
 
Intraday (n = 5)     
 
0,5 0,50 ± 0,03 5,24% 100,79%  
 
5 5,45 ± 0,04 0,79% 108,91%  
 
15 13,83 ± 0,39 2,83% 92,19% Precision = CV ≤ 15% 
 
Interday (n = 5)    Accuracy = 80-120%      
 
0,5 0,51. ± 0,02 4,86% 101,73%  
 
5 4,98 ± 0,11 2,18% 99,63%  
 






Our study found that the method used in HPLC is valid and reliable. HPLC has high selectivity and sensitivity, 
also it can measure the component of sample until nanogram limit using uv deector. Plasma has many components 
which may affect the isoniazide concentration measurement. Thus, using HPLC is appropriate method to measure 
isoniazide concentration [13]. The validation which defined in this study were system suitability, linearity, LoD and 
LoQ, accuracy and precision [8]. 
The suitability system was performed before the validation procedures to assure that HPLC can work 
appropriately during the analysis [14,16]. This suitability system test assures that the chromatography has good 
reproducibility and resolution for the analysis [17]. Linearity was performed to understand the association between 
the real concentration of isoniazide and the instrument response [16,18]. 
Accuracy was defined to assure that the method used in the analysis can show the concentration of sample is 
almost similar to the real concentration [14]. The precision was performed to assure that the repeated measurement 
has similar results of concentration [16,18]. 
Previous study about rifampicin validation method for TDM using stirbar-sorptive extraction/HPLC-UV showed 
that the method could be applied in real situation due to the similar effectivity to liquid-liquid extraction/HPLC-UV. 
The intraassay and interassay precision and accuracy were performed in the concentration less than 25.0 
microgram/mL and had the results of less than 10%. Other parameters also met the criteria for validation [19]. 
However, previous other study used Hydrophylic Interaction Liquid Chromathoghraphy (HILIC). The benefit of 
using HILIC was the ion-pair reagent of mobile phase was free detected. This method could be applied in the TDM 
method, due to the precision and accuracy were less than 10% and the limit of quantification was 4 ng/ml for 
isoniazid and rifampicin [21]. In the HPLC method, the modification of mobile phase component is required due to 
the character of the drugs. In this study, isoniazid has hydrophilic character thus we only used acetonitrile and 
aquabidest as the mobile phase. 
The other method for TDM of antituberculosis is matrix-assisted laser desorption/ionization source equipped 
with tandem time-of-flight (MALDI-TOF/TOF) mass spectrometry. This method was introduced by Sirgel et al and 
presented that the minimal concentration detected using this method was until 0.08 pmol/microL) [20]. The 
qualitative method of rifampicin and isoniazid ingestion also performed in previous study using non-invasive 
method. This procedure presented that the qualitative method was as effective as the method used in HPLC [21]. 
Many methods have been performed in the previous studies with valid results of antituberculosis TDM method. 
However, we need to consider the instrument which is available in our country such as HPLC-UV. Regarding to the 
budget in performing the TDM method, it is not possible to do the TDM in all tuberculosis patients. We need to 
make the priority for patients selection such as; ineffective treatment and patients with multidrug resistance of 
antituberculosis. 
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CONCLUSION 
 
According to the results it can be concluded that the use of HPLC has met the criteria of accuracy, precision, 
suitability of the system, linearity, LoD and LoQ. Such methods have validity in accordance with the required 
Anonymous (2001) and Anonymous (2005) so that the validation method can be used to establish the levels of INH in the 
plasma in the handling of patients with tuberculosis as well as an effort to monitor the effectiveness of treatment in the 
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